Adrian Rawcliffe
CIK 1555851 · Chief Executive Officer · last filed 2025-12-10
Adrian Rawcliffe is a Chief Executive Officer who has filed 49 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for WVE, was dated Dec 10, 2025. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.04M
3
49
-$2.30M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | Director | 54,700 | $5.87 | $321.1K | -$739.4K | 12 | 2025-12-10 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Executive Officer | 44,327 | $0.06 | $2.6K | -$518.7K | 30 | 2025-02-20 |
| ASND | CEO and CFO | 3,318 | $218.06 | $723.5K | -$1.04M | 7 | 2019-09-03 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-10 | WVE | Mixed | — | -$379.3K | EDGAR |
| 2025-11-14 | WVE | Sell (S) | −16,115 | -$109.4K | EDGAR |
| 2025-08-13 | WVE | Grant (A) | +12,700 | $0 | EDGAR |
| 2025-02-20 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −30,601 | -$17.8K | EDGAR |
| 2025-01-15 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −59,569 | -$34.6K | EDGAR |
| 2024-08-14 | WVE | Grant (A) | +16,115 | $0 | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −39,384 | -$27.6K | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −29,202 | -$24.7K | EDGAR |